A) Geodon B) Prolixin C) Risperdal D) Zyprexa
A) Invega B) Zyprexa C) Clozaril D) Abilify
A) Zyprexa B) Abilify C) Invega D) Seroquel
A) Abilify B) Seroquel C) Risperdal D) Zyprexa
A) Geodon B) Risperdal C) Seroquel D) Abilify
A) Olanzapine B) Ziprasidone C) Clozapine D) Quetiapine
A) Ziprasidone B) Aripriprazole C) Risperidone D) Paliperidone
A) Clozaril B) Geodon C) Seroquel D) Risperdal
A) Aripiprazole B) Paliperidone C) Ziprasidone D) Clozapine
A) Risperdone B) Quetiapine C) Olazapine D) Paliperidone
A) Clozapine and Aripiprazole B) Risperidone and Paliperidone C) Clozapine and Risperadone D) Aripiprazole and Paliperidone
A) 1 B) 2-5 C) 4-5 D) 1-3
A) 6 B) 24 C) 18 D) 12
A) FALSE B) TRUE
A) Minimize side effects of medication B) Develop more adaptive coping skills C) Foster patients' medication compliance D) Prevent relapse into another psychotic episode
A) directly after discontinuation of medication B) six months after discontinuation of medication C) several weeks after discontinuation of medication D) one year after discontinuation of medication
A) Symmetrel B) Thorazine C) Clozaril D) Artane
A) increased effectiveness for positive, negative, and disorganized symptoms B) enhanced efficacy in treatment-resistant patients C) weight gain more common D) tardive dyskinesia more common
A) Risperidone B) Clozapine C) Haloperiodol D) Prochlorperazine
A) Alcohol B) Stimulants C) Anticonvulsants D) Anxiolitics
A) Alcohol B) Merperidine C) Beta blockers D) Halperiodol
A) Anticonvulsants B) Beta blockers C) Antacids D) Nicotine
A) Alcohol B) Beta blockers C) SSRIs D) Tricyclic antidepressants
A) TRUE B) FALSE
A) Drug holidays B) Tobacco use C) Alcohol use D) Male gender
A) FALSE B) TRUE
A) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications. B) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia. C) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. D) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia.
A) Acute dystonia B) Ataxia C) Akathesia D) Akinesia
A) Neuroleptic Malignant Syndrome B) Postural hypotension C) Gynecomastia D) Agranulocytosis
A) TRUE B) FALSE
A) FALSE B) TRUE
A) agonize the normal dopamine-mediated inhibition of prolactin release. B) block D2 receptors in the pituitary gland and decrease prolactin secretion. C) antagonize the normal dopamine-mediated inhibition of prolactin release. D) block D2 receptors in the pituitary gland and inhibit prolactin secretion.
A) neuroendocrine changes B) hungry hungry hippos C) receptor binding and DA turnover D) molecular structure
A) Butyrophenones B) Sleepykoaladones C) Phenothiazines D) Thioxanthenenes
A) Weak; high; higher B) Weak; high; lower C) Potent; low; higher D) Potent; low; lower
A) Anhedonia B) Formal thought disorder C) Delusions D) Hallucinations
A) Neurological disorders B) Endocrine disorders C) Metabolic disorders D) Autoimmune diseases E) All of the above
A) Hallucinogens B) Alcohol C) All of the above D) Stimulants E) Opioids
A) TRUE B) FALSE
A) All of the above. B) negative symptoms of Schizophrenia. C) disorganized symptoms of Schizophrenia. D) positive symptoms of Schizophrenia.
A) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. C) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake. D) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake.
A) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. B) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. C) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine.
A) increased rates of firing B) increased rates of synthesis C) increased tap dancing D) increased release of dopamine
A) piperideines B) aliphatics C) piperazines D) thioxanthenes
A) all of the above B) genecomastia C) menstrual irregularity D) galactorrhea
A) Symmetrel (amantadine) B) Artane (trihexphenidyl) C) Cogentin (benztropine) D) Inapsine (droperiodol) E) Benadryl (diphenhydramine)
A) FALSE B) TRUE
A) polypharmacy B) superior impact on positive symptoms C) comparative lack of EPS D) actual impact at the biological level
A) Haldol B) Clozaril C) Invega D) Abilify
A) Risperdal B) Clorazil C) Seroquel D) Geodon |